{"organizations": [], "uuid": "14f90b80d9f320275951a912eb380025dba6dac2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180406.html", "section_title": "Archive News &amp; Video for Friday, 06 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-thrombogenics-announces-positive-p/brief-thrombogenics-announces-positive-preclinical-data-on-thr-149-idUSFWN1RI0TC", "country": "US", "domain_rank": 408, "title": "BRIEF-Thrombogenics Announces Positive Preclinical Data On THR-149", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.936, "site_type": "news", "published": "2018-04-06T13:45:00.000+03:00", "replies_count": 0, "uuid": "14f90b80d9f320275951a912eb380025dba6dac2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-thrombogenics-announces-positive-p/brief-thrombogenics-announces-positive-preclinical-data-on-thr-149-idUSFWN1RI0TC", "ord_in_thread": 0, "title": "BRIEF-Thrombogenics Announces Positive Preclinical Data On THR-149", "locations": [], "entities": {"persons": [], "locations": [{"name": "picomolar potencies", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nanomolar", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 6 (Reuters) - THROMBOGENICS NV:\n* ANNOUNCES THAT POSITIVE PRECLINICAL DATA ON PLASMA KALLIKREIN (PKAL) INHIBITORS IN DIABETIC MACULAR EDEMA (DME) HAVE BEEN PUBLISHED IN JOURNAL OF MEDICINAL CHEMISTRY\n* POSITIVE OUTCOMES OF PKAL INHIBITORS ON TISSUE EDEMA SUPPORTS THEIR DEVELOPMENT AS POSSIBLE TREATMENTS FOR DME AND DR VIA A VEGF-INDEPENDENT MECHANISM\n* PRECLINICAL STUDY CONFIRMED THAT BICYCLIC PEPTIDES HAVE NANOMOLAR TO PICOMOLAR POTENCIES, ARE STABLE IN BIOLOGICAL MATRICES AND REPORTED PROLONGED RETENTION IN EYE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-06T13:45:00.000+03:00", "crawled": "2018-04-07T16:15:55.000+03:00", "highlightTitle": ""}